Current:Home > NewsAn experimental Alzheimer's drug outperforms one just approved by the FDA -Ascend Wealth Education
An experimental Alzheimer's drug outperforms one just approved by the FDA
Charles H. Sloan View
Date:2025-04-06 21:41:09
Patients in the early stages of Alzheimer's may soon have a new option to stave off the loss of memory and thinking.
In a study of more than 1,700 people, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%, scientists reported at the Alzheimer's Association International Conference in Amsterdam.
The result, published simultaneously in the journal JAMA, suggests that donanemab is at least as effective as the newly approved drug Leqembi (lecanemab), which was found to reduce progression by about 27%.
"This is the biggest effect that's ever been seen in an Alzheimer's trial for a disease-modifying drug," says Dr. Daniel Skrovonsky, director of research and development at Eli Lilly, which makes donanemab.
The company has submitted the results to the Food and Drug Administration and expects a decision by the end of the year.
But experts caution that donanemab is no cure, and that its benefit amounts to only about a seven-month delay in the loss of memory and thinking.
"I do think that will make a difference to people," says Dr. Reisa Sperling, who directs the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital in Boston. "But we have to do better."
Early treatment is key
Donanemab, like Leqembi, is a monoclonal antibody designed to remove a substance called beta-amyloid from the brain. Beta-amyloid tends to form sticky plaques in the brains of people with Alzheimer's.
The donanemab study focused on people whose brain scans showed plaques and other changes associated with early Alzheimer's. They had only mild cognitive symptoms.
Even within that group, though, people with more advanced disease saw less benefit from the drug.
"What we saw is that the ability to slow disease progression is strongest if you catch this disease earlier," Skrovonsky says.
The study also suggests that patients may not need monthly intravenous infusions of donanemab for life.
Patients were taken off the drug once the plaques in their brains were mostly gone, usually within a year. The plaques did not reappear during the 18-month study, and the benefit to memory and thinking continued.
That appears to give donanemab an edge over Leqembi, which requires ongoing treatment. But it's still not clear whether donanemab's benefits will persist for years after treatment ends.
"I imagine in the future we'll have this initiation phase where we knock down plaque and then we'll have maintenance therapy," Sperling says.
Both donanemab and Leqembi can cause dangerous swelling or bleeding in the brain.
In the donanemab study, brain scans revealed this side effect in about 25% of patients. About 6% had symptoms, like headache, nausea, and confusion. Three patients died.
A new era for Alzheimer's treatment?
The results with both donanemab and Leqembi provide strong evidence that removing amyloid from the brain can slow down Alzheimer's. That approach, known as the amyloid hypothesis, had been in doubt after dozens of other amyloid drugs failed to help patients.
One reason for the recent success is earlier treatment, Sperling says. Instead of treating patients who've already sustained significant brain damage from Alzheimer's, researchers have focused on people whose brains are still relatively healthy.
Another factor is the way researchers are approaching treatment, Sperling says.
"We've learned to be more aggressive with dosing," she says, which quickly reduces amyloid to very low levels in the brain.
But scientists still aren't sure which forms of amyloid offer the best target.
Single amyloid molecules appear to be harmless. But scientists have learned that when these molecules begin to clump together, they can take on forms that are toxic. Eventually, these clumps end up in plaques between brain cells.
"There's been a debate in our field for 30 years now about whether the plaques themselves are causing the problem," Sperling says. And the results with donanemab and leqembi are unlikely to end that debate.
Donanemab is designed to target plaques specifically. Leqembi is designed to target other forms of amyloid, though it also removes plaques.
Yet both drugs appear to slow down the loss of memory and thinking, in patients with early Alzheimer's.
A study Sperling is involved in could help answer the amyloid question by treating people who still have very little plaque in their brains.
"If we see benefit even at that stage," Sperling says, "one might argue it's not just plaque" eroding memory and thinking.
veryGood! (28)
Related
- Former longtime South Carolina congressman John Spratt dies at 82
- Lift Your Face in Just 5 Minutes and Save $80 on the NuFace Toning Device on Prime Day 2023
- Summer School 1: Planet Money goes to business school
- Despite a Changing Climate, Americans Are ‘Flocking to Fire’
- What were Tom Selleck's juicy final 'Blue Bloods' words in Reagan family
- How to Watch the 2023 Emmy Nominations
- Science Day at COP27 Shows That Climate Talks Aren’t Keeping Pace With Planetary Physics
- Holiday Traditions in the Forest Revive Spiritual Relationships with Nature, and Heal Planetary Wounds
- Most popular books of the week: See what topped USA TODAY's bestselling books list
- Your air conditioner isn't built for this heat. 5 tips can boost performance
Ranking
- Sarah J. Maas books explained: How to read 'ACOTAR,' 'Throne of Glass' in order.
- Could the U.S. still see a recession? A handy primer about the confusing economy
- Kevin Costner Ordered in Divorce Docs to Pay Estranged Wife Christine $129K Per Month in Child Support
- Denied abortion for a doomed pregnancy, she tells Texas court: 'There was no mercy'
- Jorge Ramos reveals his final day with 'Noticiero Univision': 'It's been quite a ride'
- Emmy Nominations 2023 Are Finally Here: See the Full List
- Corn Nourishes the Hopi Identity, but Climate-Driven Drought Is Stressing the Tribe’s Foods and Traditions
- The Best Portable Grill Deals from Amazon Prime Day 2023: Coleman, Cuisinart, and Ninja Starting at $20
Recommendation
Juan Soto praise of Mets' future a tough sight for Yankees, but World Series goal remains
Pregnant Kourtney Kardashian Bares Her Baby Bump in Leopard Print Bikini During Beach Getaway
As Emissions From Agriculture Rise and Climate Change Batters American Farms, Congress Tackles the Farm Bill
An experimental Alzheimer's drug outperforms one just approved by the FDA
Trump suggestion that Egypt, Jordan absorb Palestinians from Gaza draws rejections, confusion
How to Watch the 2023 Emmy Nominations
Amazon Prime Day 2023 Deals That Make Great Holiday Gifts: Apple, Beats, Kindle, Drybar & More
Make Your Life Easier With 25 Problem-Solving Products on Sale For Less Than $21 on Prime Day 2023